Physician profile
Tabitha B Fortt
NPI 1427050426
$3,528.88
in general payments reported to CMS, 2019-2025
20 companies · $443 in 2025
The $443 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $572 · 2021: $514 · 2022: $527 · 2023: $350 · 2024: $432 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,178.45 | 2019-2025 | Farxiga, Breztri |
| Pfizer INC. | $597.95 | 2019-2025 | |
| Novo Nordisk INC | $288.11 | 2019-2024 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $257.90 | 2019-2024 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $246.32 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $202.33 | 2019-2023 | Linzess |
| Endo Pharmaceuticals INC. | $166.92 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.59 | 2019-2023 | Jardiance |
| Scilex Pharmaceuticals INC. | $93.06 | 2020-2022 | |
| Emmaus Medical, INC. | $65.15 | 2020-2022 | |
| Allergan, INC. | $47.03 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $41.22 | 2022 | |
| Gilead Sciences, INC. | $33.35 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $32.00 | 2024-2025 | Zoryve |
| Amgen INC. | $23.67 | 2023 | Repatha |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22.52 | 2025 | |
| Novartis Pharmaceuticals Corporation | $18.80 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $17.85 | 2025 | Neffy |
| Eisai INC. | $16.87 | 2021 | |
| Phadia US INC. | $14.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Fortt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.